Blueprint Medicines Corporation

01/28/2022 | Press release | Distributed by Public on 01/28/2022 07:08

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis